【药物名称】
化学结构式(Chemical Structure):
参考文献No.42924
标题:Monomeric and dimeric heterocycles, and therapeutic uses thereof
作者:Tamiz, A.P.; Araldi, G.L.; Kozikowski, A.P. (Georgetown University)
来源:WO 0020390
合成路线图解说明:

Addition of 4-chlorophenylmagnesium bromide (II) to arecoline (I) in Et2O at -10 C afforded the corresponding 4-arylpiperidine-3-carboxylate as a mixture of trans (III) and cis (IV) isomers. After chromatographic isolation of the racemic cis isomer (IV), resolution employing dibenzoyl-D-tartaric acid furnished the dextro enantiomer (cis)(+)-(IV). Its epimerization in the presence of NaOMe produced a 1:5.6 mixture of cis/trans isomers, from which the major compound (-)-(trans)(III) was isolated by flash chromatography. Acid hydrolysis of its methyl ester group provided carboxylic acid (V), that was further converted to acid chloride (VI) using oxalyl chloride (1,2). Finally, coupling of (VI) with 1,8-octanediamine (VII) gave the title diamide.

参考文献No.581846
标题:Application of the bivalent ligand approach to the design of novel dimeric serotonin reuptake inhibitors
作者:Tamiz, A.P.; Johnson, K.M.; Wang, C.Z.; Kozikowski, A.P.; Zhang, J.; Zhang, M.
来源:J Am Chem Soc 2000,122(22),5393
合成路线图解说明:

Addition of 4-chlorophenylmagnesium bromide (II) to arecoline (I) in Et2O at -10 C afforded the corresponding 4-arylpiperidine-3-carboxylate as a mixture of trans (III) and cis (IV) isomers. After chromatographic isolation of the racemic cis isomer (IV), resolution employing dibenzoyl-D-tartaric acid furnished the dextro enantiomer (cis)(+)-(IV). Its epimerization in the presence of NaOMe produced a 1:5.6 mixture of cis/trans isomers, from which the major compound (-)-(trans)(III) was isolated by flash chromatography. Acid hydrolysis of its methyl ester group provided carboxylic acid (V), that was further converted to acid chloride (VI) using oxalyl chloride (1,2). Finally, coupling of (VI) with 1,8-octanediamine (VII) gave the title diamide.

Drug Information Express,Drug R&D,Chemical Database,Patent Search.
Copyright © 2006-2024 Drug Future. All rights reserved.Contact Us